Novo Nordisk: FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ — Novo Nordisk today announced that the…